appli dna scienc inc apdn hold exclus agreement cannabi industri creat opportun remain
cautiou capit need maintain hold analyst anthoni vendetti full summari
new beverag corp hold revenu beat oper loss wider expect adjust
estim morinda maintain hold analyst anthoni vendetti full summari
bluebird bio inc hold potenti eu approv horizon zytenglo lentiglobin ema decis expect
inc buy pt anti-inflammatori space emerg chapter gilead
turtl beach corpor hear buy pt manag meet reinforc confid ep guidanc
excl roccat conserv reiter buy rate analyst nehal chokshi full summari
corpor event call maxim salesperson inform
inmun inc inmb cover mccarthi ndr nyc ceo dr rj tesi cfo david moss tue apr
navig hold ltd nvg cover jang group luncheon new york ceo david butter wed apr
pm et
tuanch limit tc cover jang ndr boston cfo troy mao investor relat dana cheng mon
tuanch limit tc cover jang ndr nyc cfo troy mao investor relat dana cheng tue
tuanch limit tc cover jang ndr san francisco cfo troy mao investor relat dana cheng
tuanch limit tc cover jang ndr chicago cfo troy mao investor relat dana cheng fri
cover jang ndr boston ceo gari vogel cfo frank decostanzo
director strategi busi develop costa tsoutsoplid tue apr
maxim group industri confer nyc mygr host sullivan
inc cover ndr dalla svp cfo taylor vice-president financ
investor relat treasuri mika ware mon may
corpor cover ndr milwauke evp cao cfo mark wolfing
svp financ robert verostek tue may
inc cover klee ndr nyc ceo steve picket cfo ahlstrom tue apr
inc cover klee ndr boston ceo steve picket cfo ahlstrom wed apr
inc cover klee ndr chicago ceo steve picket cfo ahlstrom thu apr
pareteum corpor cover klee ndr chicago founder execut chairman princip
execut offic turner presid deni mccarthi corpor develop investor relat laura
pareteum corpor cover klee ndr dalla founder execut chairman princip
execut offic turner presid deni mccarthi corpor develop investor relat laura
annual silicon valley bu tour host chokshi tue jul
manag meet reinforc confid ep
guidanc excl roccat conserv reiter
headwind midpoint ep guidanc continu expect roccat
prove accret sharehold valu
remain confid guidanc conserv
reiter buy rate price target
headwind midpoint ep guidanc continu expect roccat
prove accret sharehold valu recent host ndr
ceo juergen stark came away meet increas confid
assert roccat acquisit repres headwind
midpoint ep guidanc figur new slide updat slide deck
detail expect impact roccat top- bottom-lin
explicit statement roccat headwind net
incom guidanc consist assert dec
earn call take-away note remain enthus valu expect roccat
creat result expans strong ip strong brand
recognit momentum specif hear expand game
consol headset north america world-wide includ
slice pc game headset mice keyboard north america europ
total world-wide pc game peripher market ip note roccat
core ip design mice keyboard previous state
expect take year hear bring market intim manag
final respect strong brand recognit momentum note roccat
name best game keyboard ahead logitech
remain confid guidanc conserv note revenu either
exclud roccat acquisit y/i impli instal base
valu growth y/i includ roccat acquisit y/i
impli season remaind typic season
level given quarter row provid above-consensu
quarter-out guidanc maintain conserv multi-quart outlook
streak inclin believ full-year guidanc
conserv especi given strong guidanc anniversari
tough comparison note legitim reason manag cite
caution rel impli below-season outlook due slower
upgrade/replac cycl amongst new headset user although seem
case given season guidanc weaker slate game
expect would come bear market slowdown due rumbl
new consol releas xbox playstat may come fruition
earli thu impact headset demand level said recent meet
manag reinforc confid ep guidanc exclud
headwind roccat acquisit conserv
reiter buy rate price target given initi
guidanc appear conserv yet larg in-lin initi
expect increas confid initi work demonstr
game peripher market secular growth market due cloud-bas game
guidanc reason reflect expect declin increment user
still increas instal base follow record influx due
fortnit phenomena given strong brand hear wield
evidenc headset sold cumul headset player
year row valu see march press releas highli confid
hear continu earn peripher standard gm rang logitech
logi hold gm hear gm give us
confid well-abov consensu ep estim consensu
note short interest remain high current continu
util multipl ep estim consist rest
compani coverag lead price target
click full note
exclus agreement cannabi industri creat
opportun remain cautiou capit need
march apdn announc exclus suppli chain licens
agreement theracann privat cannabi hemp consult
sell apdn certaint authent technolog cannabi hemp
apdn expect receiv per month begin april
end august moreov addit minimum
annual payment requir theracann year three impli
revenu recognit sept payment expect increas
approxim year minimum annual payment
year
due exclus definit agreement expect revenu
futur fiscal year increas faster initi estim therefor
increas revenu estim narrow ep loss
bottom line though apdn exclus licens agreement theracann present
larg revenu opportun cannabi market maintain hold rate
stock due quarterli fluctuat well addit capit like
requir end posit view recent cannabi deal surround
one preval issu industri transport cannabi
provid law enforc personnel clear proof product sourc processor
state origin could help avoid unnecessari arrest furthermor
theracann recoup invest apdn recoup cost associ
track technolog apdn theracann agre revenu split
expect begin believ apdn authent solut
provid cannabi compani seamless applic overcom legal
logist headwind industri given develop compani outlook
turn posit remain cautiou base apdn capit structur
potenti need rais capit end
estim revenu unchang widen
loss per share estim due model
capit rais sept instead
revis estim result theracann agreement increas
revenu estim
respect also narrow loss per share estim
widen ep loss
respect wider loss per share estim attribut
lack clariti expect recogn revenu theracann deal year two
valuat apdn current trade ev/revenu estim compar
peer averag believ slight discount peer justifi due
compani cash burn rate capit structur
click full note
revenu beat oper loss wider
expect adjust estim morinda maintain hold
report revenu estim believ due day
morinda revenu follow acquisit oper loss
wider expect due primarili acquisition-rel cost
adjust estim account addit morinda
expect provid total revenu historically-st
gross margin oper margin ebitda margin
bottom line would remain sidelin transform
primarili multi-level market compani decemb
acquisit morinda hold inc believ compani acquir stabl cash
flow posit busi morinda complement legaci direct-stor deliveri
dsd beverag busi anticip dsd busi also remain
rel stabl continu ebitda posit brand portfolio provid
greatest revenu upsid compani secur addit point distribut
launch new product on-trend categori face execut issu
past manag intend increas market brand drive outsiz
growth repres signific up-front invest moreov given small
proport revenu current provid brand believ could take
time brand scale signific impact overal
financi perform therefor maintain hold rate
result summari today market open report net
revenu y/i estim in-line
consensu believ beat primarili driven inclus morinda
revenu start gross margin y/i
estim consensu oper loss wider
estim believ primarili due cost associ
morinda acquisit compani yet report loss per share
also publish detail balanc sheet year-end expect metric
file due monday april
guidanc reiter guidanc origin issu investor
present file march expect net revenu
least new estim consensu gross
margin in-line new estim consensu
ebitda least estim in-line
consensu
revis estim due acquisit morinda rais
revenu estim respect
project morinda busi grow roughli y/i repres
total revenu dsd busi estim y/i repres
revenu final expect legaci brand portfolio rebound inventori
issu grow y/i reach revenu believ morinda
busi relatively-st mid-singl digit oper margin legaci
busi continu burn cash compani look grow brand portfolio
base assumpt increas ep
estim respect
valuat trade ev/ebitda estim significantli
peer averag beverag peer averag
page detail compar valuat analysi believ
fairly-pr base dcf analysi discount rate
click full note
potenti eu approv horizon zytenglo
announc posit opinion chmp recommend condit
market author zytenglo gene therapi transfusion-
depend -thalassemia tdt eu zytenglo approv would usher
first gene therapi tdt first approv therapi bluebird
follow chmp opinion eu market decis expect
nda file expect later year
event northstar northstar updat
data tdt tdt expect late
assum eha european hematolog associ june
american societi hematolog decemb sickl cell program
expect initi see data
well decemb updat around car-t program also
expect
durabl data two phase trial well two on-going phase trial data
summar mainli stem meet decemb
tdt
patient transfus independ month maintain
hemoglobin g/dl septemb median durat month
genotyp patient tdt genotyp year
transfusion-depend tdt patient
eleven patient least three month follow-up avail
data cut-off patient stop receiv transfus
hemoglobin level g/dl time last studi visit month
post-treat level patient rang g/dl
significantli contribut total hemoglobin percent
one pediatr tdt patient
mutat sever patient three patient
novemb total hemoglobin greater g/dl last
assess includ pediatr patient patient transfus follow
lentiglobin treatment last assess month patient last
transfus month post-treat last assess month six patient
last transfus month post-treat last assess
manufactur capac increas earlier month compani open state-
of-the-art manufactur facil nc produc lentiviru
gene cell therapi program plan hire addit personnel facil
bring total
click full note
anti-inflammatori space emerg chapter
gilead finch studi read-out posit
gilead galapago nv glpg nr report posit data two
studi inhibitor filgotinib treat rheumatoid arthriti ra
recal trial read-out three trial
met primari endpoint well multipl secondari endpoint
filgo potenti treat wide rang ra patient demonstr
trial prior inadequ respons methotrex inadequ
respons biolog methotrex naiv data
week one endpoint week week
shown import also safeti data may favor
vs compet drug develop upadacitinib abbvi nr
data come later year
filgo next sovaldi/harvoni gilead goe without say
anti-inflammatori market huge look humira alon gener
one caveat space unlik hcv hiv like come
competit safeti profil even modest efficaci
differ could set one player apart anoth gilead also target
indic multipl studi on-going equat
psoriat arthriti tortuga ankylos spondyl divers
crohn select ulcer coliti
transit toward commercial-stag pend approv still go
take time yet factor filgotinib
advanc program ra long-term data finch trial
expect also watch manta trial safeti data
 testicular toxic lag behind finch trial
enrol perspect though acceler
trial site ramp come gilead eye one next chapter anti-
inflammatori new manag
background methotrex enrol patient
moder sever ra inadequ respons methotrex random
patient receiv filgotinib filgo filgo
adalimumab placebo patient stabl dose
methotrex primari endpoint proport patient achiev american
colleg rheumatolog percent respons week
secondari patient stabl background
placebo
placebo
placebo
diseas activ rate filgo non-inferior
clinic remiss filgo superior adalimumab
filgo filgo filgo
week modifi total sharp score mtss chang
methotrex naiv on-going enrol patient
moder sever ra methotrex naiv random patient
methotrex primari endpoint proport patient
achiev respons week secondari
signific filgo alon
filgo alon
filgo alon
filgo filgo alon
filgo alon
modifi total sharp score mtss chang filgo
filgo filgo alon
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
